Dr. Enzelberger will be located in Basel where he will play a central role in the launch of future newcos from Versant's Ridgeline Discovery Engine.
He is a seasoned executive with deep domain knowledge of drug discovery and development, especially in the protein field. He most recently was CSO and a member of the management board of MorphoSys. He joined the company in 2002 and is recognized as an authority in the field of protein engineering.
Dr. Enzelberger holds a Ph.D. from the Technical University of Stuttgart, Germany.